CTA: cancer-testis antigen; KK-LC-1: Kita-Kyushu lung cancer antigen-1; MAGE-A3: melanoma antigen family A3; NY-ESO-1: New York esophageal squamous cell carcinoma 1; SSX4: synovial sarcoma, X breakpoint 4; VCX2: variable charge, X-linked 2.
Declarations
Acknowledgments
The authors thank Sylva Petrocchi for editorial assistance and R. G. Lisziewicz for contributions to the peptide selection strategy. Language editing support was provided using ChatGPT (OpenAI).
Author contributions
JL: Conceptualization, Methodology, Writing—original draft, Writing—review & editing. JMM: Conceptualization, Writing—original draft, Writing—review & editing. AH: Software. AS: Formal analysis, Software, Visualization. TK: Software, Formal analysis. BGP: Supervision. MBB: Supervision. FL: Validation. CMMC: Resources. AM: Validation. MMV: Investigation. SM: Resources. All authors read and approved the submitted version of the manuscript.
Conflicts of interest
JL is a shareholder of VERDI Solutions GmbH. Authors AS, TK, and AH are employed at VERDI Solutions GmbH. All other authors declare no conflicts of interest.
Ethical approval
The personalized VERDI vaccine was administered under an individual healing attempt protocol in accordance with Article 37 of the Declaration of Helsinki, Version 2013. Approval by an institutional ethics committee was not required under applicable regulations.
Consent to participate
Informed consent to participate in the study was obtained from the participant.
Consent to publication
Not applicable.
Availability of data and materials
The data presented in this study are available upon reasonable request from the corresponding author.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Lisziewicz RG, Oviedo F, Szasz AG, Ferres JL, Lori F, Lisziewicz J. HLA-genotype-based Predictive Diagnosis of T-cell Responses to SARS-CoV-2 Infection Powered by Machine Learning.Med Res Arch. 2023;11:11. [DOI]
Dolina JS, Lee J, Brightman SE, McArdle S, Hall SM, Thota RR, et al. Linked CD4+/CD8+ T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression.J Clin Invest. 2023;133:e164258. [DOI] [PubMed] [PMC]
Ostroumov D, Fekete-Drimusz N, Saborowski M, Kühnel F, Woller N. CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Cell Mol Life Sci. 2018;75:689–713. [DOI] [PubMed] [PMC]
Petrou C, Sarigiannis Y. Peptide synthesis: Methods, trends, and challenges. In: Koutsopoulos S, editor. Peptide Applications in Biomedicine, Biotechnology and Bioengineering. Woodhead Publishing: Cambridge; 2018. pp. 1–21. [DOI]
Fukuyama T, Futawatari N, Ichiki Y, Shida A, Yamazaki T, Nishi Y, et al. Correlation Between Expression of the Cancer/Testis Antigen KK-LC-1 and Helicobacter pylori Infection in Gastric Cancer.In Vivo. 2017;31:403–7. [DOI] [PubMed] [PMC]
Fukuyama T, Futawatari N, Yamamura R, Yamazaki T, Ichiki Y, Ema A, et al. Expression of KK-LC-1, a cancer/testis antigen, at non-tumour sites of the stomach carrying a tumour.Sci Rep. 2018;8:6131. [DOI] [PubMed] [PMC]
Ansari S, Nikpour P. Identification of Cancer/Testis Antigens Related to Gastric Cancer Prognosis Based on Co-Expression Network and Integrated Transcriptome Analyses.Adv Biomed Res. 2023;12:52. [DOI] [PubMed] [PMC]
Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma.Cancer Res. 2006;66:4922–8. [DOI] [PubMed]
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med. 2012;366:883–92. [DOI] [PubMed] [PMC]
Butterfield LH. Cancer vaccines.BMJ. 2015;350:h988. [DOI] [PubMed] [PMC]
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer.Lancet. 2020;396:635–48. [DOI] [PubMed]
Wilke H, Muro K, van Cutsem E, Oh S, Bodoky G, Shimada Y, et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol. 2014;15:1224–35. [DOI] [PubMed]
Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies.Int J Mol Sci. 2020;21:4012. [DOI] [PubMed] [PMC]
Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge.World J Gastroenterol. 2015;21:11428–38. [DOI] [PubMed] [PMC]
Picard M, Castells MC. Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review.Clin Rev Allergy Immunol. 2015;49:177–91. [DOI] [PubMed]
Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.J Immunother Cancer. 2018;6:51. [DOI] [PubMed] [PMC]
Serin GM, Mahmutoglu AS, Polat Ş, Aksoy E, Tanyeri H. Internal jugular vein thrombosis as an initial presentation of signet-ring cell adenocarcinoma of unknown origin.J Med Cases. 2011;2:156–8. [DOI]
Dourdouna M, Tatsi E, Syriopoulou V, Michos A. Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity.Diagn Microbiol Infect Dis. 2023;106:115948. [DOI] [PubMed] [PMC]
Katsikis PD, Ishii KJ, Schliehe C. Challenges in developing personalized neoantigen cancer vaccines.Nat Rev Immunol. 2024;24:213–27. [DOI] [PubMed] [PMC]
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.Nature. 2023;618:144–50. [DOI] [PubMed] [PMC]
Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.Nat Rev Clin Oncol. 2021;18:215–29. [DOI] [PubMed] [PMC]
Li H, Zong Z, Zhou T, Sun L, Wang A, Zhang K, et al. Trends of incidence and survival in patients with gastroenteropancreatic signet ring cell carcinoma: an analysis from the Surveillance, Epidemiology, and End Results program.J Gastrointest Oncol. 2019;10:979–88. [DOI] [PubMed] [PMC]
Eichler H, Pignatti F, Schwarzer-Daum B, Hidalgo-Simon A, Eichler I, Arlett P, et al. Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth.Clin Pharmacol Ther. 2021;109:1212–8. [DOI] [PubMed] [PMC]
